Roche's CD20/CD3 bispecific antibody Lunsumio successfully reached the primary endpoint in the critical phase III CELESTIMO study for follicular lymphoma.

Zhitongcaijing · 3d ago
Roche's CD20/CD3 bispecific antibody Lunsumio successfully reached the primary endpoint in the critical phase III CELESTIMO study for follicular lymphoma.